'Not Approvable' Letter Thwarts Nanosphere's Hopes to Launch FDA-Approved Plavix PGx Test

"The issuance of the [FDA 'not approvable'] letter means that the company will encounter a delay in its plans to commercialize this product in the US," Nanosphere said in a statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.